US › Healthcare

Citius Pharmaceuticals Inc (CTXR)

US · Healthcare · Biotechnology

$0.59+4.98%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$1.5M

Net profit

$-8.9M

EPS

$-0.34

EPS estimate

$-0.36

Net margin

-593.3%

EPS came in at -0.34 against a street estimate of -0.36 — a beat of 5.6%.

Key statistics

Market cap

$15.9M

Forward P/E

0.3

P/B

0.24

Book value

$2.43

EPS (TTM)

$-1.75

52-week high

$2.19

52-week low

$0.47

50-day MA

$0.59

200-day MA

$0.75

Beta

1.00

Analyst view

Analysts rate Citius Pharmaceuticals Inc a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $4.00.

Shareholding

Insiders

1.80%

Institutions

4.95%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	0.90%
Vanguard Capital Management, LLC	0.61%
Miller Financial Services LLC	0.47%
Vanguard Fiduciary Trust Co	0.28%
BlackRock Inc	0.25%
HRT FINANCIAL LLC	0.22%
Asset Advisory Group, INC.	0.21%
UBS Group AG	0.20%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Citius Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.